Abstract bekijken

Deze abstract is toegekend aan sessie SBO-BOG Free papers: Glaucome/Glaucoma

Titel

A 3-month period’s evaluation of compliance with Travalert®

Doel	To study if there is a change in compliance over the time when using Travalert®
Methodes	Travalert® is a computerized bottle holder that reminds patients to instill their drops, assists in the administration of the drops, and records the dosing time for travoprost (Travatan®) or travoprost/timolol fixed combination (Duotrav®), (Alcon, Inc., Fort Worth, TX). This monitoring device helps healthcare providers to discern between insufficient drug efficacy and non-compliance and so, make good decisions. Non compliance as recorded by Travalert® results when few drops are recorded or when drops are not taken during the proper time interval. In this study, the patient was considered not compliant when few drops were recorded. Patients with ocular hypertension or any type of glaucoma treated by Travatan® or Duotrav® were recruited when attending their follow-up visit. The records were analyzed and discussed with the patients
Resultaten	11/23 patients approached accepted to take part in the study ; 9 females; age : 35-81 years. For all the patients involved, self-reported compliance (SRC) was better than recorded compliance (RC). After the first month’s study, one patient withdrew and another one was asked to stop and was operated on, as we had the evidence of non compliance, (what we had suspected). For all the patients but one that completed the study, RC was better at month-II than at month-I of Travalert® use. This improvement in compliance persisted over the 3-month study period
Conclusie	As it has already been reported, patients overestimate their level of compliance. Compliance was improved by Travalert® use and this effect lasted during the 3-month study period. The majority (8/9) of the patients chose to continue using Travalert®

Auteur 1

Naam	EHONGO
Initialen	A
Instituut	Hôpital Erasme, ULB
Stad	Bruxelles